Protocol: Effect of intravitreal bevacizumab (Avastin) in the treatment of macular edema: A systematic review of randomized controlled trials

Journal of Research in Medical Sciences

Volumn 17, Issue 12, 2012, Pages 1180-1187

  Qazi, Hammad A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Avastin; Protocol; Systematic review

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

CONJUNCTIVAL HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; EYE INFLAMMATION; HUMAN; INTRAOCULAR PRESSURE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; RETINA TEAR; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

EID: 84875076666     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. JohnsonMW. Perspective, etiology and treatment of macular edema. Am J Ophthalmol 2009;147:11-21.
2. TranosPG, WickremasingheSS, StangosNT, ToupozisF, TsinopoulosI, PavesioCE. Macular edema. Surv Ophthalmol 2004;49:470-90.
3. BandelloF, PognuzR, PolitoA, PirracchioA, MenchiniF, Ambesi M. Diabetic macular edema: Classification, medical and laser therapy. Semin Ophthalmol 2003;18:251-8.
4. CatierA, TadayoniR, PaquesM, ErginayA, HaouchineB, Gaudric A. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005;140:200-6.
5. MarkomichelakisNN, HalkiadakisI, PanteliaE, PeponisV, PatelisA, TheodossiadisP. Patterns of macular edema in patients with uveitis: Qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2004;111:946-53.
6. SourdilleP, SantiagoPY. Optical coherence tomography of macular thickness after cataract surgery. JCataract Refract Surg 1999;25:256-61.
7. VaranoM, ScassaC, RipandelliG, CapaldoN. New diagnostic tools for Macular Edema. Doc Ophthalmol 1999;97:373-9.
8. SivaprasadS, McCluskeyP, LightmanS. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand 2006;84:722-3.
9. TelanderDG, CessnaCT. Macular edema, Irvine-Gass. Available from: http://www.emedicine.medscape.com/article/1224224-overview. [Last accessed on 2010Mar5].
10. Prieto-del-CuraM, Gonzalez-GuijarroJ. Complications of uveitis: Prevalence and risk factors in a serie of 398cases. Arch Soc Esp Oftalmol 2009;84:523-8.
11. GiustiC, ForteR, VingoloEM. Clinical pathogenesis of macular holes in patients affected by Retinitis Pigmentosa. Eur Rev Med Pharmacol Sci 2002;6:45-8.
12. AdackaparaCA, SunnessJS, DibernardoCW, MeliaBM, Dagnelie G. Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. Retina 2008;28:103-10.
13. DonaldsonMJ, PulidoJS, HermanDC, DiehlN, HodgeD. Pars planitis: A20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol 2007;144:812-7.
14. Ortega-LarroceaG, Arellanes-GarciaL. Pars planitis: Epidemiology and clinical outcome in a large community hospital in Mexico City. Int Ophthalmol 1995;19:117-20.
15. StewartJM, CubillanLD, Cunningham ET Jr. Prevalence, clinical features, and causes of vision loss among patients with ocular toxocariasis. Retina 2005;25:1005-13.
16. WuTT, AminiL, LefflerCT, SchwartzSG. Cataracts and cataract surgery in mentally retarded adults. Eye Contact Lens 2005;31:50-3.
17. TingTD, OhM, CoxTA, MeyerCH, TothCA. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthal 2002;120:731-7.
18. BonnetM, PayanX. Long-term prognosis of cystoid macular edema after microsurgery of rhegmatogenous retinal detachment. J Fr Opthalmol 1993;16:259-63.
19. ParravanoM, MenchiniF, VirgiliG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009;4:CD007419.
20. IannettiL, AccorintiM, LiveraniM, CaggianoC, AbdulazizR, Pivetti-PezziP. Optical coherence tomography for classification and clinical evaluation of macular edema in patients with uveitis. Ocul Immunol Inflamm 2008;16:155-60.
21. GoatmanKA. Areference standard for the measurement of macular oedema. Br J Ophthalmol 2006;90:1197-202.
22. Cunha-VazJG, LoboC, SousaJC, OliveirosB, LeiteE, Faria de AbreuJR. Progression of retinopathy and alteration of the blood-retinal barrier in patients with type2 diabetes: Aseven-year prospective follow-up study. Graefes Arch Clin Exp Ophthalmol 1998;236:264-8.
23. FongDS, SegalPP, MyersF, FerrisFL, HubbardLD, DavisMD. Subretinal fibrosis in diabetic macular edema. ETDRS report 23 Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997;115:873-7.
24. MavrikakisE, LamWC, KhanBU. Macular edema, diabetic. Available from: http://www.emedicine.medscape.com/article/1224224-overview. [Last accessed on 2010Mar5].
25. Lopes de FariaJM, JalkhAE, TrempeCL, McMeelJW. Diabetic macular edema: Risk factors and concomitants. Acta Ophthalmol Scand 1999;77:170-5.
26. HendersonBA, KimJY, AmentCS, Ferrufino-PonceZK, GrabowskaA, CremersSL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg 2007;33:1550-8.
27. OzakiH, HayashiH, VinoresSA, MoromizatoY, CampochiaroPA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997;64:505-17.
28. DerevjanikNL, VinoresSA, XiaoWH, MoriK, TuronT, HudishT, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 2002;43:2462-7.
29. KendallC, WooltortonE. Rosiglitazone(Avandia) and macular edema. CMAJ 2006;174:623.
30. FerraraN, HillanKJ, NowotnyW. Bevacizumab(Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
31. Genentech. Avastin(Bevacizumab). Available from: http://www.gene.com/gene/products/information/oncology/avastin. [Last accessed on 2010 Feb 25].
32. PrestaLG, ChenH, O'ConnorSJ, ChisholmV, MengYG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
33. HurwitzHI, FehrenbacherL, HainsworthJD, HeimW, BerlinJ, Holmgren E, et al. Bevacizumab plus irnotecan, fluorouracil and leucovorin for metastatic colorectal cancer. NEngl J Med 2004;350:2335-42.
34. YangJC, HarworthL, SherryRM, HwuP, SchwartzentruberDJ, Topalian SL, et al. Arandomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for mewztastatic renal cancer. NEngl J Med 2003;349:427-34.
35. Food and drug administration(FDA) US. U.S. BL 125085/168 Amendment: Bevacizumab Genentech, Inc. (Renal Cell Carcinoma): Final draft. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfmfuseaction=Search.Label_ApprovalHistory#apphist. [Last accessed on 2010Feb25].
36. Wikipedia, the free encyclopedia. (27th Feb, 2010). Bevacizumab. Available from: http://www.en.wikipedia.org/wiki/Bevacizumab. [Last accessed on 2010Mar01].
37. HouJ, TaoY, JiangYR, LiXX, GaoL. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: Amatched study. Chin Med J(Engl) 2009;122:2695-9.
38. GuthoffR, MeigenT, Henne MannK, SchraderW. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion-a matched-Pairs analysis. Ophthalmologica 2010;224:126-32.
39. YanyaliA, AytugB, HorozogluF, NohutcuAF. Bevacizumab(Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-6.
40. MirshahiA, NamavariA, DjalilianA, MoharamzadY, ChamsH. Intravitreal bevacizumab(avastin) for the treatment of cystoid macular edema in behçet disease. Ocul Immunol Inflamm 2009;17:59-64.
41. ArevaloJF, SanchezJG, WuL, MaiaM, AlezzandriniAA, BritoM, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009;116:1488-97.
42. LamDS, LaiTY, LeeVY, ChanCK, LiuDT, MohamedS, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: Six-month results of a randomized controlled trial. Retina 2009;29:292-9.
43. MiyakeT, SawadaO, KakinokiM, SawadaT, KawamuraH, Ogasawara K, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth. Factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010;51:1606-8.
44. AndrioloRB, PugaME, Belfort JuniorR, AtallahAN. Bevacizumab for ocular neovasculardiseases: Asystematic review. Sao Paulo Med J 2009;127:84-91.
45. TakamuraY, KuboE, AkagiY. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009;116:1151-7.
46. Cordero ComaM, SobrinL, OnalS, ChristenW, FosterCS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 2007;114:1574-9.
47. SoheilianM, RamezaniA, ObudiA, BijanzadehB, SalehipourM, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50.
48. RussoV, BaroneA, ConteE, PrascinaF, StellaA, NociND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 2009;29:511-5.
49. AhmadiehH, RamezaniA, ShoeibiN, BijanzadehB, TabatabaeiA, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9.
50. FaghihiH, RoohipoorR, MohammadiSF, Hojat-JalaliK, Mirshahi A, Lashay A, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-8.
51. PaccolaL, CostaRA, FolgosaMS, BarbosaJC, ScottIU, JorgeR. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema(IBEME study). Br J Ophthalmol 2008;92:76-80.
52. RothovaA, Suttorp-van SchultenMS, TreffersWF, KijlstraA. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6.
53. TaylorHR. LXIII Edward Jackson Memorial Lecture: Eye care: Dollars and sense. Am J Ophthalmol 2007;143:1-8.
54. Gutiérrez JC, BarquetLA, CaminalJM, Mitjana, AlmoldaSP, Domènech NP, et al. Intravitreal bevacizumab(Avastin) in the treatment of macular edema secondary to retinal vein occlusion. Clin Ophthalmol 2008;2:787-91.
55. Lanzagorta-ArestiA, Palacios-PozoE, Menezo RozalenJL, Navea-TejerinaA. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: A pilot study. Retina 2009;29:530-5.
56. ChoWB, OhSB, MoonJW, KimHC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009;29:516-22.
57. SteigerwaltR, BelcaroG, CesaroneMR, Di RenzoA, GrossiMG, RicciA, et al. Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. JOcul Pharmacol Ther 2009;25:537-40.
58. KaiserPK. Prospective evaluation of visual acuity assessment: Acomparison of snellen versus ETDRS charts in clinical practice(An AOS Thesis). Trans Am Ophthalmol Soc 2009;107:311-24.
59. IzquierdoNJ, EmanuelliA, IzquierdoJ, GarciaM, CarmanC, Maria B. Foveal thickness and macular volume in patients with oculocutaneous Albinism. Retina 2007;27:1227-30.
60. GroverDA, LiT, ChongCC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008;1:CD005656.
61. SchulzKF, GrimesDA. Generation of allocation sequences in randomised trials: Chance, not choice. Lancet 2002;359:515-9.
62. SchulzKF, GrimesDA. The Lancet Handbook of Essential Concepts in Clinical Research. Edinburgh(UK): Elsevier; 2006.
63. Assessing risk of bias in included studies. Chapter8. In: HigginsJP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version5.0.0(updated February 2008). The Cochrane Collaboration; 2008. Available from: http://www.cochrane-handbook.org. [Last accessed on 2010Mar 3].
64. Analysing data and undertaking meta-analyses. Chapter9. In: DeeksJJ, HigginsJP, GreenS, editors. Cochrane Handbook for Systematic Reviews of Interventions Version5.0.0(updated February 2008). The Cochrane Collaboration; 2008. Available from: http://www.cochrane-handbook.org. [Last accessed on 2010 Mar 15].
65. SmithTS, NanjiAA, GreenbergPB. Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2008;10:CD007325.
66. SimhaA, BraganzaA, AbrahamL, SamuelP, LindsleyK. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev 2009;3:CD007920.
67. GohD, LimN. Prophylactic non-steroidal anti-inflammatory agents for the prevention of cystoid macular oedema after cataract surgery. Cochrane Database Syst Rev 2007;3:CD006683.
68. Cochrane data base. Chapter16: Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions Version5.0.0(updated February 2008). The Cochrane Collaboration; 2008. Available from: http://www.cochranehand-book. Org. [Last accessed on 2010 Mar 21].
69. Cochrane, chapter9: Analyzing data and undertaking meta analysis. In: HigginsJPT, ThompsonSG, DeeksJJ, AltmanDG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
70. Cochrane Handbook for Systematic Reviews of Interventions Version5.0.0(updated February 2008). The Cochrane Collaboration; 2008. Available from: http://www.cochrane-handbook.org. [Last accessed on 2010 Mar 29].